Navigation Links
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
Date:8/24/2009

ALISO VIEJO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. While retigabine was generally well tolerated, the study did not meet its pre-specified primary efficacy endpoint. Further detailed analyses are warranted and are ongoing.

"As is typical in many proof-of-concept studies, these results are inconclusive at this time with regard to the potential utility of retigabine in PHN patients," stated J. Michael Pearson, chairman and chief executive officer. "The treatment duration was relatively short and with limited statistical powering for the study overall. There are many additional analyses that have yet to be undertaken and these will be performed over the next several months. Moreover, given that the provisional results from this study will not impact the submission of our New Drug Application for retigabine in epilepsy, we remain focused on the submission as our number one priority."

The study was a randomized, double-blind, placebo-controlled Phase IIa proof-of-concept study with 187 patients randomized 2:1 of retigabine versus placebo for a treatment period of up to 10 weeks. The study was conducted in approximately 50 trial locations. Study patients were titrated to their individually determined maximum tolerated dose within the range of 300 mg to 900 mg per day. The primary outcome assessment was the comparison of the average pain intensity over the last seven days of maintenance therapy with retigabine versus placebo. Pain intensity was measured on a standard 0 - 10 num
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals Reports Second Quarter Financial Results
2. Valeant to Acquire Tecnofarma, A Mexican Generic Company
3. Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009
4. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
5. Valeant Announces Increase to Securities Repurchase Program
6. Valeant to Acquire Polish Dermatology Company
7. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
10. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
11. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 Agein.com, the Internet’s premier anti-aging web ... of the foremost experts in the industry, is releasing its ... this winter. , “The official start of winter is still ... been hit with an icy blast. After one of the ... 2015 will usher in another brutal winter,” says Dr. Kevin ...
(Date:11/28/2014)... Brosix is always making changes to its ... a more efficient, effective, and secure experience. Most recently, ... 1. The ability to setup local servers for each ... service customers around the globe. , 2. The ability ... customers that require millions of users in one network. ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Dr. ... cosmetic dermatologists , announced the addition of Dr. Bridgit ... Nolan joins the practice after having completed her dermatology ... Medicine. , Dr. Walder invited Dr. Nolan ... in medicine, surgery and cosmetic dermatology. Not only does ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... are continuing to move forward in New Jersey’s ... claims in a consolidated litigation established there is ... Case List updated on November 18th shows 1,293 ... was created for lawsuits that allege complications resulting ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Miami's Plastic ... website. Practice founder Dr. Jeffrey Epstein ... Created using a groundbreaking WordPress platform, the site is ... , Currently, up to 75% of all prospective ... ever, these people are logging on with smartphones, tablets, ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2
... Molecular & Cell Biology at Boston University Henry M. ... at Boston University School of Medicine discovered recently a ... expression. The study describing this work titled, "Mpk1 MAPK ... Termination," appears in the March 4 issue of ...
... new, rapid blood test that could lead to early ... thousands of people stricken with fungal meningitis, a leading ... closer to market with a recent collaboration between the ... "The ability to quickly identify yeast infection in ...
... 4 (HealthDay News) -- Children are more likely to ... playgrounds in their neighborhoods, researchers report. The study ... give their opinions about outdoor public spaces in their ... children spent watching television, using the computer and playing ...
... trial process in the United States is on shaky ... are increasingly defined by specific genetic and biologic markers ... therapies grow smaller and smaller. Coupled with skyrocketing costs ... are essential in bringing new and effective therapies to ...
... THURSDAY, March 3 (HealthDay News) -- More young people are ... engaging in same-sex encounters, according to a new report detailing ... from interviews with 13,500 men and women aged 15 to ... that more than half of young people under age 24 ...
... (HealthDay News) -- The brain,s so-called reward center actually responds ... causing fear, finds a new study in mice. The ... help explain why some people are thrill-seekers. Pleasurable or ... a bridge, can trigger the production of dopamine, a neurotransmitter ...
Cached Medicine News:Health News:Novel mechanism for control of gene expression revealed 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 3Health News:To bring effective therapies to patients quicker, use the team approach 2Health News:To bring effective therapies to patients quicker, use the team approach 3Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3
(Date:11/26/2014)... , Nov. 26, 2014  Perrigo Company plc ... global provider of "Quality Affordable Healthcare Products®," today announced ... relating to the sale of 6,809,210 ordinary shares at ... the full exercise of the option to purchase up ... Securities LLC and Barclays Capital Inc., as representatives of ...
(Date:11/26/2014)... 26, 2014  Genomic Health, Inc. (Nasdaq: GHDX ... Chief Executive Officer and President, will participate in the ... The New York Palace Hotel in New ... am Eastern Time (ET). To access the ... go to the  Investor Relations  section of the company,s ...
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and CEO of Regulus, will present ... Piper Jaffray Healthcare Conference at the New York Palace ... EST.  The presentation will be webcast at the time ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3
... WOODCLIFF LAKE, N.J., Oct. 29 Eisai Inc. and the ... recipient of the 2009 C.A.R.E. Pharmacy Award. , ... is being recognized for the critical role she has played ... disease. As a Geriatric Consultant Pharmacist with the Riverside ...
... , CHARLOTTE, N.C., Oct. 29 MedCath Corporation (Nasdaq: MDTH ) will host ... from its fourth quarter ended September 30, 2009. The company will issue a press ... What: Fourth Quarter Earnings Conference Call, ... How: Dial-in conference call, ...
Cached Medicine Technology:Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 2Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 3MedCath Corporation to Hold Conference Call on Fourth Quarter Results 2
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: